Final results of a phase 2, open ‐label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high‐risk myelodysplastic syndrome

Cancer, EarlyView.

Source: Cancer - April 16, 2018 Category: Cancer & Oncology Authors: RitaAssiMD , Hagop M.KantarjianMD , Tapan M.KadiaMD , NaveenPemmarajuMD , EliasJabbourMD , NitinJainMD , NavalDaverMD , ZeevEstrovMD , TaisukeUeharaPhD , TakashiOwaPhD , Jorge E.CortesMD , GautamBorthakurMD Source Type: research